/C O R R E C T I O N -- Coventry/
Coventry First LLC and its Executive Chairman Alan H. Buerger have filed a Motion to Dismiss a lawsuit brought by Abacus Global Management (NASDAQ: ABL) in the U.S. District Court for the Middle District of Florida. The motion, filed on September 2, 2025, argues that Abacus's lawsuit attempts to suppress constitutionally protected debate.
A key development supporting Coventry's position is that Lapetus Solutions, Abacus's primary life expectancy provider, ceased operations on August 31, 2025. Buerger emphasizes that transparent discussion about life expectancy estimates and industry practices is crucial for investors, regulators, and the overall life settlement market.
Coventry First LLC e il suo Presidente Esecutivo Alan H. Buerger hanno presentato una mozione di respingimento riguardo a una causa intentata da Abacus Global Management (NASDAQ: ABL) presso la Corte Distrettuale degli Stati Uniti per il Middle District della Florida. La mozione, depositata il 2 settembre 2025, sostiene che la causa di Abacus cerchi di sopprimere un dibattito protetto costituzionalmente.
Un elemento chiave a sostegno della posizione di Coventry è che Lapetus Solutions, il principale fornitore di stime di aspettativa di vita di Abacus, ha cessato le attività il 31 agosto 2025. Buerger sottolinea che un confronto trasparente sulle stime di aspettativa di vita e sulle pratiche del settore è fondamentale per investitori, regolatori e per il mercato complessivo delle life settlement.
Coventry First LLC y su presidente ejecutivo Alan H. Buerger han presentado una moción para desestimar una demanda interpuesta por Abacus Global Management (NASDAQ: ABL) en el Tribunal de Distrito de los Estados Unidos para el Distrito Medio de Florida. La moción, presentada el 2 de septiembre de 2025, argumenta que la demanda de Abacus pretende suprimir un debate protegido constitucionalmente.
Un hecho relevante que respalda la posición de Coventry es que Lapetus Solutions, el principal proveedor de estimaciones de esperanza de vida de Abacus, cesó sus operaciones el 31 de agosto de 2025. Buerger enfatiza que el debate transparente sobre las estimaciones de esperanza de vida y las prácticas del sector es crucial para inversores, reguladores y el mercado de life settlements en general.
Coventry First LLC와 그 총괄 회장 Alan H. Buerger는 Abacus Global Management (NASDAQ: ABL)가 플로리다 중부 지방 연방지방법원에 제기한 소송을 기각해 달라는 동의신청을 제출했습니다. 이 동의신청은 2025년 9월 2일 제출되었으며, Abacus의 소송이 헌법적으로 보호되는 토론을 억압하려 한다고 주장합니다.
Coventry의 입장을 뒷받침하는 주요 사실은 Abacus의 주요 기대수명 제공업체인 Lapetus Solutions가 2025년 8월 31일자로 운영을 중단했다는 점입니다. Buerger는 기대수명 추정치와 업계 관행에 대한 투명한 논의가 투자자, 규제당국 및 전체 생명보험정산(life settlement) 시장에 중요하다고 강조합니다.
Coventry First LLC et son président exécutif Alan H. Buerger ont déposé une requête en rejet d’une action intentée par Abacus Global Management (NASDAQ: ABL) devant le tribunal fédéral des États-Unis pour le Middle District de Floride. La requête, déposée le 2 septembre 2025, soutient que la plainte d’Abacus cherche à réprimer un débat protégé par la Constitution.
Un développement clé appuyant la position de Coventry est que Lapetus Solutions, le principal fournisseur d’estimations d’espérance de vie d’Abacus, a cessé ses activités le 31 août 2025. Buerger souligne que des discussions transparentes sur les estimations d’espérance de vie et les pratiques du secteur sont cruciales pour les investisseurs, les régulateurs et le marché des life settlements dans son ensemble.
Coventry First LLC und dessen Executive Chairman Alan H. Buerger haben einen Antrag auf Abweisung einer Klage eingereicht, die Abacus Global Management (NASDAQ: ABL) beim US-Bezirksgericht für den Middle District of Florida eingereicht hatte. Der am 2. September 2025 eingereichte Antrag führt aus, dass Abacus’ Klage versucht, verfassungsrechtlich geschützte Debatten zu unterdrücken.
Ein wesentlicher Aspekt, der Coventrys Position stützt, ist, dass Lapetus Solutions, Abacus’ Hauptanbieter für Lebenserwartungsprognosen, den Betrieb am 31. August 2025 eingestellt hat. Buerger betont, dass eine transparente Auseinandersetzung über Lebenserwartungsschätzungen und Branchenpraktiken für Investoren, Aufsichtsbehörden und den gesamten Life-Settlement-Markt von zentraler Bedeutung ist.
- Motion to Dismiss highlights First Amendment protection for industry debate
- Development regarding Lapetus shutdown supports Coventry's position
- Legal dispute could create uncertainty for stakeholders
- Shutdown of Lapetus Solutions affects Abacus's life expectancy assessment capabilities
In the news release, Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit, issued 02-Sep-2025 by Coventry over PR Newswire, we are advised by the company that the first paragraph, last sentence, should read "The full Motion to Dismiss" rather than "The full Complaint" as originally issued. The complete, corrected release follows:
Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit
Motion underscores that Abacus's claims lack merit as Lapetus, its key life expectancy provider, shut its doors August 31
In the filing, Coventry and Mr. Buerger express their view that Abacus's lawsuit is an effort to silence constitutionally protected debate. As the Motion states:
"The First Amendment expresses 'a profound national commitment to the principle that debate on public issues should be uninhibited, robust, and wide-open.' Abacus, however, seeks to flip that principle on its head. Faced with criticism about serious problems of its own making, Abacus brought this meritless lawsuit to muzzle those who have highlighted the truth or expressed their constitutionally protected opinions. That it cannot do."
The Motion also highlights that Abacus invested in and relied heavily upon Lapetus Solutions, Inc. ("Lapetus") as its primary life expectancy provider — but Lapetus publicly announced that it shut down all operations effective August 31, 2025. This development underscores the concerns raised regarding Abacus's practices and the importance of open debate about the life settlement industry.
"Abacus's complaint is an attempt to silence robust debate on important issues affecting the life settlement industry, including the reliability of life expectancy estimates," said Mr. Buerger. "Transparent disclosures advance the interests of investors, regulators, and the life settlement market as a whole, and the First Amendment protects the right to voice opinions and concerns, particularly on matters of such public interest."
About Coventry
Coventry is the leader and creator of the secondary market for life insurance. For more than 20 years, we have been driving the industry forward and expanding opportunities for life insurance policyowners. Coventry's deep experience combined with a fierce commitment to consumer rights makes Coventry the clear market leader, a position we use to raise industry standards and expand consumer choice. To date, we have delivered more than
Media Contacts:
Prosek Partners for Coventry
Andy Merrill / Kiki Tarkhan
Pro-Coventry@prosek.com
View original content:https://www.prnewswire.com/news-releases/coventry-and-alan-buerger-move-to-dismiss-abacus-lawsuit-302544419.html
SOURCE Coventry
FAQ
What is the lawsuit between Coventry First and Abacus Global Management (NASDAQ: ABL) about?
Why did Coventry file a Motion to Dismiss against Abacus's lawsuit?
What happened to Lapetus Solutions and how does it affect Abacus (ABL)?
How does the First Amendment relate to Coventry's Motion to Dismiss against Abacus?
What are the implications of this legal dispute for the life settlement industry?
